In clinics, G-CSF and biosimilars are used to treat patients with neutropenia during intensive chemotherapy and for mobilization of hematopoietic stem cells in the circulation (Gazitt, 2002; Mehta et al., 2015; Hsu and Cushing, 2016). Here, CSF3 is linked to Decreased total neutrophil count.